Certara Management

Management criteria checks 2/4

Certara's CEO is Bill Feehery, appointed in Jun 2019, has a tenure of 5.42 years. total yearly compensation is $7.81M, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 1.38% of the company’s shares, worth €23.67M. The average tenure of the management team and the board of directors is 2.3 years and 5.4 years respectively.

Key information

Bill Feehery

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage	10.2%
CEO tenure	5.4yrs
CEO ownership	1.4%
Management average tenure	2.3yrs
Board average tenure	5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Feehery's remuneration changed compared to Certara's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$31m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$61m
Dec 31 2023	US$8m	US$796k	-US$55m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	US$19m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$6m	US$796k	US$15m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$6m	US$773k	-US$13m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$4m	US$773k	-US$49m
Sep 30 2020	n/a	n/a	-US$965k
Jun 30 2020	n/a	n/a	US$601k
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$4m	US$438k	-US$9m

Compensation vs Market: Bill's total compensation ($USD7.81M) is above average for companies of similar size in the German market ($USD1.65M).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.

CEO

Bill Feehery (53 yo)

5.4yrs

Tenure

US$7,810,028

Compensation

Dr. William F. Feehery, also known as Bill, Ph.D. serves as Chief Executive Officer of the Certara, Inc. since June 2019 and Director since 2012. He had been the President of Industrial Biosciences Busines...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Feehery	CEO & Director	5.4yrs	US$7.81m	1.38% € 23.7m
Leif Pedersen	President & Chief Commercial Officer	1.3yrs	US$2.14m	0.062% € 1.1m
John Gallagher	SVP, Principal Accounting Officer & Chief Financial Officer	1.6yrs	US$4.24m	0.011% € 194.4k
Robert Aspbury	President of Certara Scientific Software	4.8yrs	US$2.09m	0.18% € 3.0m
Patrick Smith	President of Certara Drug Development Solutions	3yrs	US$2.42m	0.031% € 534.4k
Daniel Corcoran	Chief Counsel	less than a year	no data	no data
Ron DiSantis	Senior Vice President of Corporate Development	no data	no data	no data
Sheila Rocchio	Chief Marketing Officer	1.4yrs	no data	no data
Rona Anhalt	Chief Human Resources Officer	less than a year	no data	no data
Frederic Bois	Senior Scientific Advisor	5.6yrs	no data	no data
David Mitchell	Senior Vice President of Strategic Engagement	3.2yrs	no data	no data
Hannah Jones	Senior VP & Head of PBPK Consulting Services	no data	no data	no data

2.3yrs

Average Tenure

53yo

Average Age

Experienced Management: 700's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Feehery	CEO & Director	5.4yrs	US$7.81m	1.38% € 23.7m
Frederic Bois	Senior Scientific Advisor	5.6yrs	no data	no data
James Cashman	Independent Chairman of the Board	6.5yrs	US$319.51k	0.28% € 4.9m
Matthew Walsh	Independent Director	4.3yrs	US$252.01k	0.12% € 2.0m
Eran Broshy	Independent Director	2.3yrs	US$252.01k	0.014% € 245.5k
Malcolm Rowland	Chair of Simcyp Scientific Advisory Board	no data	no data	no data
Yuichi Sugiyama	Member of Simcyp Scientific Advisory Board	no data	no data	no data
Nancy Killefer	Independent Director	3.3yrs	US$252.01k	0.015% € 257.7k
Donald Mager	Member of Simcyp Scientific Advisory Board	no data	no data	no data
Geoff Tucker	Member of Simcyp Scientific Advisory Board	no data	no data	no data
Lawrence Lesko	Member of Simcyp Scientific Advisory Board	9.3yrs	no data	no data
J Houston	Member of Simcyp Scientific Advisory Board	no data	no data	no data

5.4yrs

Average Tenure

65yo

Average Age

Experienced Board: 700's board of directors are considered experienced (5.4 years average tenure).

Certara Management

Management criteria checks 2/4

Key information

Recent management updates

Certara, Inc. Appoints John Reynders as Independent Board Member

Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel

Certara, Inc., Annual General Meeting, May 21, 2024

Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company

Certara, Inc. Appoints David Spaight to the Board of Directors

Independent Director recently sold €172k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.009 loss per share (vs US$0.31 loss in 3Q 2023)

Certara, Inc. Updates Earnings Guidance for the Year 2024

Certara, Inc. Appoints John Reynders as Independent Board Member

Certara, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Certara, Inc. (NasdaqGS:CERT) completed the acquisition of ChemAxon Kft.

Certara, Inc. Launches Phoenix™ Version 8.5 Drug Development Software

Certara, Inc. Reiterates Earnings Guidance for the Year 2024

Certara, Inc. (NasdaqGS:CERT)signed a definitive agreement to acquire ChemAxon Kft.

Certara, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software

Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel

Certara, Inc. Reiterates Earnings Guidance for the Year 2024

Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform

Certara, Inc., Annual General Meeting, May 21, 2024

Certara, Inc. to Report Q1, 2024 Results on May 07, 2024

Certara, Inc. Provides Earnings Guidance for the Year 2024

Certara, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC.

Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software

Certara, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.025 profit in 3Q 2022)

Certara, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Certara, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.03 (vs US$0.004 loss in 2Q 2022)

New major risk - Share price stability

Certara, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: EPS: US$0.009 (vs US$0.014 in 1Q 2022)

Certara, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$0.094 (vs US$0.089 loss in FY 2021)

Certara, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Certara, Inc. (NasdaqGS:CERT) acquired VYASA Analytics LLC.

Forecast breakeven date pushed back to 2023

Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company

Arsenal Capital Partners completed the acquisition of an additional 18.8% stake in Certara, Inc. (NasdaqGS:CERT) from EQT Avatar Parent L.P.

Certara, Inc. Appoints David Spaight to the Board of Directors

Now 21% undervalued after recent price drop

Independent Director recently sold €172k worth of stock

Third quarter 2022 earnings released: EPS: US$0.025 (vs US$0.012 loss in 3Q 2021)

Certara, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Japan's Pharmaceuticals and Medical Devices Agency Renews Licenses of Certara's Software for Evaluating Regulatory Submissions

Certara, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Insider recently sold €3.1m worth of stock

Now 21% undervalued

Certara, Inc. Announces Resignation of Justin Edge as President of Regulatory and Access, Effective September 1, 2022

Second quarter 2022 earnings released: US$0.004 loss per share (vs US$0.019 loss in 2Q 2021)

Certara, Inc. Revises Its Full Year Earnings Guidance of 2022

Certara, Inc. Introduces Update of Pinnacle 21(Tm) Enterprise and New Pinnacle 21(Tm) Data Exchange Module

Certara, Inc. Appoints Rosemary A. Crane, as a Class III Director, Effective July 21, 2022

Certara, Inc. Appoints Eran Broshy as New Independent Board Member, Effective July 11, 2022

Certara, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

Certara, Inc. Announces New Versions of Biosimulation Software for Development of Novel Biologics

Insider recently sold €4.6m worth of stock

First quarter 2022 earnings released: EPS: US$0.014 (vs US$0.007 in 1Q 2021)

Certara, Inc. Reiterates Earnings Guidance for the Year 2022

Certara, Inc. to Report Q1, 2022 Results on May 05, 2022

Certara, Inc. Announces Committee Changes

Certara, Inc. Announces Resignation of Dr. Carol Gallagher, Member of the Board of Directors, Chair of the Compensation Committee, and Member of the Nominating and Corporate Governance Committee

Insider recently sold €4.5m worth of stock

Certara, Inc. Revises Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

U.S. Food and Drug Administration Licenses Certara, Inc.’s Immunogenicity Simulator

Certara, Inc. Receives 90% of New Drug Approvals by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Review

Certara, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Certara, Inc. Announces Release of Pinnacle 21 Enterprise Software

Certara, Inc. Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

Independent Chairman of the Board Sherilyn S. McCoy has left the company

Certara, Inc. Announces Update of D360 Scientific Informatics Software

Insider recently sold €9.9m worth of stock